Financings in Brief: Biogen
This article was originally published in The Gray Sheet
Executive Summary
Biogen: Biotech firm says it will repurchase up to 2.5 mil. shares of common stock "from time to time over the next two years, depending on market conditions." The repurchased shares will be used "for general corporate purposes, such as stock to be issued under employee stock option and stock purchase plans," Biogen notes...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.